Can the ESPRIT results end the antiplatelet battle between neurologists and cardiologists?
Gregory W Albers
Correspondence Neurology and Neurological Sciences, Stanford University, 701 Welch Road # 325, Stanford, CA 94305, USA
Email albers@stanford.edu
Cardiologists have been hesitant to prescribe extended-release dipyridamole and aspirin for stroke prevention in patients with cardiovascular disease because of concerns that this combination might increase the risk of cardiac events. Here, Gregory Albers reviews new ESPRIT data, which demonstrate that the combination is more effective than aspirin alone for the prevention of stroke in patients with a recent cerebrovascular event, and does not increase cardiac risk. Cardiologists should now be reassured that dipyridamole and aspirin is appropriate for patients with recent stroke and cardiovascular disease.
Full text of this article is available with one of the following:
- Personal subscription Purchase your own personal subscription to this journal. Already a subscriber? Please log in for immediate access.
- 7 day single article pass for US$18 In order to purchase this article you must be a registered user. Please register or log in.
- Site licence Learn more about institutional site licences
Current Subscribers
Please log in to access the full text article using the login box at the top of the page.
